Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Suspended 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Solid Tumors 1Sarcoma 1Melanoma 1

Interventions

Specimen Handling 278Magnetic Resonance Spectroscopy 233pembrolizumab 227Carboplatin 187Cisplatin 153Biopsy 148Cyclophosphamide 143Paclitaxel 133Nivolumab 122Gemcitabine 113Bevacizumab 104Radiotherapy 92Dexamethasone 86Pemetrexed 83fludarabine 77Fluorouracil 76Docetaxel 75Doxorubicin 74atezolizumab 71Radiation 71Leucovorin 70Rituximab 67Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 60Vincristine 56Cetuximab 56Lenalidomide 54Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × spartalizumab × 30 days × Clear all
NCT03958383 2026-06-03

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

University of Wisconsin, Madison

Phase 1/2 Terminated
8 enrolled 12 charts
Dermatologic

Melanoma

NCT07472153 2026-05-28

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT07612098 2026-05-28

SPARE-04

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
274 enrolled
Sarcoma

Sarcoma

NCT05155332 2026-05-20

A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)

Boehringer Ingelheim

Phase 1 Suspended
190 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡